Covered recipient · General Payments record
MANUEL E RODRIGUEZ
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$61,846.03
85 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $52,524.00 | 20 |
| Travel and Lodging | $6,339.63 | 12 |
| Food and Beverage | $2,960.24 | 52 |
| Education | $22.16 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $31,834.05 | 26 |
| Gilead Sciences, Inc. | $28,938.25 | 28 |
| ABBVIE INC. | $428.66 | 12 |
| Phathom Pharmaceuticals, Inc. | $271.87 | 4 |
| AIMMUNE THERAPEUTICS, INC. | $156.34 | 6 |
| Regeneron Healthcare Solutions, Inc. | $108.88 | 4 |
| GENZYME CORPORATION | $41.78 | 1 |
| Merck Sharp & Dohme LLC | $18.16 | 1 |
| Ardelyx, Inc. | $17.70 | 1 |
| Janssen Biotech, Inc. | $15.55 | 1 |
| Lilly USA, LLC | $14.79 | 1 |
Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANUEL E RODRIGUEZ
NPI 1356399307 · CMS profile ID 197176
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
BRADENTON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MANUEL E RODRIGUEZ, NPI 1356399307, CMS profile ID 197176, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356399307?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
85 matching records · $61,846.03 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–85 of 85.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $114.09 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964646 | CMS |
| Ardelyx, Inc. | $17.70 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146704266 | CMS |
| ABBVIE INC. | $21.13 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964642 | CMS |
| ABBVIE INC. | $14.98 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964644 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $16.18 | 08/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146976214 | CMS |
| Lilly USA, LLC | $14.79 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135149494 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.48 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114148375 | CMS |
| Phathom Pharmaceuticals, Inc. | $108.53 | 06/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151117265 | CMS |
| Phathom Pharmaceuticals, Inc. | $124.46 | 06/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151117263 | CMS |
| Janssen Biotech, Inc. | $15.55 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078401744 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $12.81 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146983459 | CMS |
| GENZYME CORPORATION | $41.78 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139939147 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.47 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114148373 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $22.40 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146975798 | CMS |
| ABBVIE INC. | $13.24 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964640 | CMS |
| Gilead Sciences, Inc. | $22.41 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133780356 | CMS |
| Gilead Sciences, Inc. | $33.37 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133780358 | CMS |
| Gilead Sciences, Inc. | $74.30 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133780360 | CMS |
| Gilead Sciences, Inc. | $262.98 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864792 | CMS |
| Gilead Sciences, Inc. | $640.20 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864794 | CMS |
| Gilead Sciences, Inc. | $1,724.88 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133864796 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.16 | 04/15/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114148371 | CMS |
| Gilead Sciences, Inc. | $48.45 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133780354 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.77 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114148369 | CMS |
| ABBVIE INC. | $14.18 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964638 | CMS |
| ABBVIE INC. | $28.77 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964636 | CMS |
| Phathom Pharmaceuticals, Inc. | $19.07 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151117261 | CMS |
| ABBVIE INC. | $28.11 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964634 | CMS |
| ABBVIE INC. | $14.75 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964632 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $13.74 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147017027 | CMS |
| Merck Sharp & Dohme LLC | $18.16 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141621128 | CMS |
| ABBVIE INC. | $22.90 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964630 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $76.99 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147017129 | CMS |
| ABBVIE INC. | $118.93 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964628 | CMS |
| ABBVIE INC. | $24.18 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105964626 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $888,567.13 | 405 |
| PY2024 | Principal investigator | $456,119.82 | 213 |
| PY2023 | Principal investigator | $216,373.00 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
405 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $32,616.00 | 12/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALIST | A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 1175345642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,616.00 | 12/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALIST | A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis ICONIC-UC | No dispute reported | 06/30/2026 | 1175345652 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,905.70 | 12/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254720 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248254725 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $86.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606002 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $250.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606007 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,864.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606033 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $86.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606041 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $250.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606045 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254249 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,277.52 | 12/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254253 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,279.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254223 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254227 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,314.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254231 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254235 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254240 |
| Principal investigator 1 | Eli Lilly and Company | $1,621.26 | 12/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187881182 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187881976 |
| Principal investigator 1 | Bausch Health US, LLC | $150.00 | 12/16/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840072 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $490.00 | 12/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248254143 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 12/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606169 |
| Principal investigator 1 | Gilead Sciences, Inc. | $80.64 | 12/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209334 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 12/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209519 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28.69 | 12/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606005 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $710.00 | 12/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253810 |
| Principal investigator 1 | Gilead Sciences, Inc. | $43.50 | 12/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209358 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 12/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209389 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $18,340.00 | 12/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253682 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $490.00 | 12/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248253614 |
| Principal investigator 1 | Gilead Sciences, Inc. | $201.00 | 12/05/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204696 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15.90 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606011 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $50.13 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606016 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $250.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606018 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $172.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606022 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $172.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606026 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $400.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606029 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $29.28 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606037 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $22.55 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606049 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253302 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253306 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,014.33 | 12/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253311 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,413.90 | 12/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253298 |
| Principal investigator 1 | Gilead Sciences, Inc. | $67.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204686 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,861.00 | 11/27/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253050 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 11/27/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253055 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 11/27/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253059 |
| Principal investigator 1 | Genentech, Inc. | $258.00 | 11/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606158 |
| Principal investigator 1 | Genentech, Inc. | $2,670.00 | 11/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606162 |
| Principal investigator 1 | Genentech, Inc. | $2,776.00 | 11/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606166 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,291.85 | 11/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252819 |
| Principal investigator 1 | Genentech, Inc. | $4,495.00 | 11/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606149 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 11/19/2025 | Non-covered Recipient Entity FLORIDA RESEARCH INSTITUTE | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177742 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $74.25 | 11/19/2025 | Non-covered Recipient Entity FLORIDA RESEARCH INSTITUTE | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177747 |
| Principal investigator 1 | Eli Lilly and Company | $12,640.00 | 11/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187881974 |
| Principal investigator 1 | Genentech, Inc. | $6,079.00 | 11/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606153 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,275.00 | 11/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209501 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,277.52 | 11/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252372 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,314.00 | 11/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252322 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,166.10 | 11/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209535 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,314.00 | 11/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252286 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,314.00 | 11/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252290 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 11/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252294 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,020.00 | 11/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248252298 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606123 |
| Principal investigator 1 | Genentech, Inc. | $11,600.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606127 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606131 |
| Principal investigator 1 | Genentech, Inc. | $5,914.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606137 |
| Principal investigator 1 | Genentech, Inc. | $123.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606145 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,910.60 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204706 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209424 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209542 |
| Principal investigator 1 | Gilead Sciences, Inc. | $650.00 | 10/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.62 | 10/27/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658664 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209317 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209341 |
| Principal investigator 1 | Gilead Sciences, Inc. | $230.50 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209380 |
| Principal investigator 1 | Gilead Sciences, Inc. | $87.00 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209432 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209457 |
| Principal investigator 1 | Gilead Sciences, Inc. | $200.00 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209480 |
| Principal investigator 1 | Gilead Sciences, Inc. | $143.50 | 10/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209487 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,397.39 | 10/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251763 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251766 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251707 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251712 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,259.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251717 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,020.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251721 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251725 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 10/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206761 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,500.00 | 10/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.14 | 10/20/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658654 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 10/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209350 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 10/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209394 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209416 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209450 |
| Principal investigator 1 | Genentech, Inc. | $883.35 | 10/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606141 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,341.90 | 10/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251481 |
| Principal investigator 1 | Gilead Sciences, Inc. | $400.00 | 10/08/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209407 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,370.00 | 10/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251303 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,314.00 | 10/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251307 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 10/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251312 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 10/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251316 |
| Principal investigator 1 | Genentech, Inc. | $142.80 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606119 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209327 |
| Principal investigator 1 | Gilead Sciences, Inc. | $150.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209365 |
| Principal investigator 1 | Gilead Sciences, Inc. | $150.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209372 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209439 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209466 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209472 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,500.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209494 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209509 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209527 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250925 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250929 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250933 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,341.90 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250937 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,341.90 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251293 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,403.95 | 10/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251297 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 10/02/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250921 |
| Principal investigator 1 | Bausch Health US, LLC | $280.00 | 09/30/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840067 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 09/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209259 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 09/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209311 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 09/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248250742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $580.75 | 09/24/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658652 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606115 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209244 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209250 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209274 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209280 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209289 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209299 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,392.98 | 09/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250534 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 09/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250140 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,403.95 | 09/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250144 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 09/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209204 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $172.00 | 09/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211606000 |
| Principal investigator 1 | Gilead Sciences, Inc. | $17,068.50 | 09/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209264 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,449.68 | 09/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249888 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 09/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249857 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 09/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206752 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,864.76 | 09/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120800 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 09/05/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249748 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 09/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204654 |
| Principal investigator 1 | Gilead Sciences, Inc. | $267.00 | 09/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204668 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 09/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249296 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,295.00 | 09/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249300 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 09/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249303 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 08/27/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204660 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,318.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211605995 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206711 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,100.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206720 |
| Principal investigator 1 | Gilead Sciences, Inc. | $575.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206727 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206735 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206744 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,014.33 | 08/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249067 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 08/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209212 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $15,516.90 | 08/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248982 |
| Principal investigator 1 | Eli Lilly and Company | $420.53 | 08/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187882402 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,259.00 | 08/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248786 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,306.29 | 08/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174916 |
| Principal investigator 1 | Bausch Health US, LLC | $1,362.44 | 08/14/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840064 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248376 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,449.68 | 08/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248084 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 08/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114504 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 08/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120813 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 08/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174920 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 08/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,953.00 | 07/28/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193314 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,632.00 | 07/28/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193328 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204675 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,900.00 | 07/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206689 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 07/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206697 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,040.00 | 07/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247361 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 07/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247320 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 07/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248247325 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,393.30 | 07/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248247260 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,000.00 | 07/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211605982 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $973.00 | 07/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211605985 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,587.00 | 07/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211605990 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,910.60 | 07/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204642 |
| Principal investigator 1 | Bausch Health US, LLC | $6,278.58 | 07/14/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840060 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 07/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114482 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,804.00 | 07/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658646 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 07/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209220 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 07/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209227 |
| Principal investigator 1 | Gilead Sciences, Inc. | $87.00 | 07/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209236 |
| Principal investigator 1 | Janssen Research & Development, LLC | $239.00 | 06/30/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193282 |
| Principal investigator 1 | Gilead Sciences, Inc. | $6,673.50 | 06/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209041 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 06/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209112 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 06/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209173 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 06/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209179 |
| Principal investigator 1 | Gilead Sciences, Inc. | $87.00 | 06/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209197 |
| Principal investigator 1 | Janssen Research & Development, LLC | $96.25 | 06/25/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193275 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 06/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206681 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 06/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173996 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,499.59 | 06/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173980 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204595 |
| Principal investigator 1 | Gilead Sciences, Inc. | $67.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204609 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $490.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245964 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,979.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245969 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,417.60 | 06/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245973 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 06/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245930 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,841.20 | 06/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245934 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,273.33 | 06/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,439.80 | 06/18/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 06/18/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658622 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 06/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204617 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 06/18/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204625 |
| Principal investigator 1 | Gilead Sciences, Inc. | $7,200.00 | 06/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206674 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 06/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177734 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,478.00 | 06/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245677 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 06/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245680 |
| Principal investigator 1 | Gilead Sciences, Inc. | $200.00 | 06/13/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204587 |
| Principal investigator 1 | Gilead Sciences, Inc. | $790.00 | 06/13/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209065 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,287.40 | 06/13/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $92.13 | 06/12/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $92.13 | 06/12/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193366 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 06/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245554 |
| Principal investigator 1 | Bausch Health US, LLC | $355.00 | 06/11/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840094 |
| Principal investigator 1 | Gilead Sciences, Inc. | $200.00 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209057 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209073 |
| Principal investigator 1 | Gilead Sciences, Inc. | $130.50 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209088 |
| Principal investigator 1 | Gilead Sciences, Inc. | $90.00 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209126 |
| Principal investigator 1 | Gilead Sciences, Inc. | $975.00 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209135 |
| Principal investigator 1 | Gilead Sciences, Inc. | $43.50 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209152 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209167 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 06/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114476 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 06/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,241.80 | 05/28/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658632 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 05/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244731 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,435.35 | 05/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244735 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,653.14 | 05/26/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173992 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 05/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209049 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 05/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606089 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,804.00 | 05/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244369 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 05/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244373 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 05/15/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243940 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,277.52 | 05/15/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243944 |
| Principal investigator 1 | Bausch Health US, LLC | $4,617.90 | 05/13/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $96.25 | 05/12/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.89 | 05/09/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 05/09/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/09/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.49 | 05/09/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658630 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 05/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173972 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 05/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174896 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,733.82 | 05/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204602 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,271.90 | 05/05/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658634 |
| Principal investigator 1 | Genentech, Inc. | $7,980.00 | 04/30/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606101 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,471.50 | 04/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114509 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,449.46 | 04/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 04/28/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193337 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 04/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242876 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,295.00 | 04/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242881 |
| Principal investigator 1 | Genentech, Inc. | $1,054.00 | 04/25/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606104 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,380.33 | 04/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248242635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $949.00 | 04/23/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.34 | 04/23/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.34 | 04/23/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.34 | 04/23/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.34 | 04/23/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658644 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,580.00 | 04/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209081 |
| Principal investigator 1 | Gilead Sciences, Inc. | $175.00 | 04/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209119 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,639.00 | 04/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209143 |
| Principal investigator 1 | Gilead Sciences, Inc. | $200.00 | 04/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209158 |
| Principal investigator 1 | Gilead Sciences, Inc. | $790.00 | 04/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209187 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 04/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242504 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 04/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242508 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 04/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242512 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $18,340.00 | 04/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242516 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242445 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,020.00 | 04/15/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242417 |
| Principal investigator 1 | Genentech, Inc. | $2,110.00 | 04/11/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606109 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 04/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242237 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $710.00 | 04/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242242 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 04/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242245 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,449.68 | 04/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242250 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $74.25 | 04/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114498 |
| Principal investigator 1 | Bausch Health US, LLC | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $225.00 | 04/07/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $161.00 | 04/07/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658614 |
| Principal investigator 1 | Genentech, Inc. | $21,100.00 | 04/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606112 |
| Principal investigator 1 | Gilead Sciences, Inc. | $7,500.00 | 04/04/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209102 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $735.75 | 04/02/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658616 |
| Principal investigator 1 | Gilead Sciences, Inc. | $67.00 | 04/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204633 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,347.00 | 04/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241495 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 04/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241500 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 04/01/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241505 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $114.75 | 03/31/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120820 |
| Principal investigator 1 | Gilead Sciences, Inc. | $167.00 | 03/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204565 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 03/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204579 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,698.03 | 03/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174912 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 03/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241222 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $250.00 | 03/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241226 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,772.00 | 03/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241114 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204515 |
| Principal investigator 1 | Gilead Sciences, Inc. | $67.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204522 |
| Principal investigator 1 | Gilead Sciences, Inc. | $317.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204529 |
| Principal investigator 1 | Gilead Sciences, Inc. | $67.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204572 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,050.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208944 |
| Principal investigator 1 | Gilead Sciences, Inc. | $90.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208952 |
| Principal investigator 1 | Gilead Sciences, Inc. | $790.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208960 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208968 |
| Principal investigator 1 | Gilead Sciences, Inc. | $317.50 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208992 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,479.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209017 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209024 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,190.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209032 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241076 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,239.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241080 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $775.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241085 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $490.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241089 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $200.00 | 03/19/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248241093 |
| Principal investigator 1 | Gilead Sciences, Inc. | $60.00 | 03/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208937 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 03/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208976 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 03/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209000 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,097.20 | 03/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $615.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,000.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,000.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 03/12/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658604 |
| Principal investigator 1 | Gilead Sciences, Inc. | $790.00 | 03/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208921 |
| Principal investigator 1 | Gilead Sciences, Inc. | $150.00 | 03/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208984 |
| Principal investigator 1 | Gilead Sciences, Inc. | $100.00 | 03/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209008 |
| Principal investigator 1 | Bausch Health US, LLC | $3,850.46 | 03/11/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840082 |
| Principal investigator 1 | Genentech, Inc. | $7,385.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606067 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114522 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173988 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174903 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174908 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177717 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $877.50 | 03/07/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,617.86 | 03/06/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.34 | 03/06/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.21 | 03/06/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658610 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 03/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174001 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $18,340.00 | 03/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248240159 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 03/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240346 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,449.67 | 03/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240350 |
| Principal investigator 1 | Genentech, Inc. | $2,110.00 | 03/05/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606080 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,428.80 | 03/05/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229208929 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,751.90 | 03/03/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248240055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.21 | 02/28/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658592 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,622.25 | 02/24/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120807 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 02/21/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606053 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $600.00 | 02/20/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $92.13 | 02/17/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193267 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $411.60 | 02/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248239777 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 02/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248239781 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $980.00 | 02/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248239785 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,295.00 | 02/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248239789 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $500.00 | 02/13/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239697 |
| Principal investigator 1 | Genentech, Inc. | $3,165.00 | 02/12/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606075 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $225.00 | 02/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248239040 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $710.00 | 02/06/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239158 |
| Principal investigator 1 | Janssen Research & Development, LLC | $518.95 | 02/05/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193304 |
| Principal investigator 1 | Janssen Research & Development, LLC | $92.13 | 02/03/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193357 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658648 |
| Principal investigator 1 | Genentech, Inc. | $16,880.00 | 01/31/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606063 |
| Principal investigator 1 | Gilead Sciences, Inc. | $167.00 | 01/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204502 |
| Principal investigator 1 | Gilead Sciences, Inc. | $30.00 | 01/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204540 |
| Principal investigator 1 | Gilead Sciences, Inc. | $334.00 | 01/29/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204547 |
| Principal investigator 1 | Bausch Health US, LLC | $850.00 | 01/28/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840076 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $162.00 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114516 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120794 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192120833 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192173983 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192174900 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $114.75 | 01/28/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,349.00 | 01/27/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193320 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $225.00 | 01/27/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238811 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,964.00 | 01/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238623 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 01/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238627 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $23,281.29 | 01/23/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238630 |
| Principal investigator 1 | Genentech, Inc. | $17,935.00 | 01/22/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606058 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.40 | 01/17/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658588 |
| Principal investigator 1 | Genentech, Inc. | $2,587.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606084 |
| Principal investigator 1 | Genentech, Inc. | $973.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606093 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211606096 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,300.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238534 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,040.00 | 01/17/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238538 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,775.00 | 01/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238403 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,065.00 | 01/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238408 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $75.00 | 01/16/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238412 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $44.00 | 01/14/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192114490 |
| Principal investigator 1 | Bausch Health US, LLC | $4,900.42 | 01/13/2025 | Non-covered Recipient Entity Florida Research Institute LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224840086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.65 | 01/13/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.40 | 01/13/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658586 |
| Principal investigator 1 | Genentech, Inc. | $15,825.00 | 01/13/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211606071 |
| Principal investigator 1 | Gilead Sciences, Inc. | $75.00 | 01/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS, LLP | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204556 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,386.00 | 01/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238350 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $350.00 | 01/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238354 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $150.00 | 01/10/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238359 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 01/09/2025 | Non-covered Recipient Entity FLORIDA DIGESTIVE HEALTH SPECIALISTS LLP | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192177738 |
| Principal investigator 1 | Janssen Research & Development, LLC | $518.95 | 01/02/2025 | Non-covered Recipient Entity Fl Dgstv Hlth Specialists Llp | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175193349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity Florida Research Institute | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis | No dispute reported | 06/30/2026 | 1220658590 |